Alzamend Neuro Inc SEC Filings

Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc. (ALZN), reported multiple transactions in September 2025 affecting both direct and indirect holdings. The filings show open-market dispositions on 09/23/2025 (43,238 shares at $2.3757) and 09/24/2025 (39,140 shares at a $2.3090 VWAP), plus a 09/25/2025 sale of 14,628 shares at $2.3126. On 09/25/2025 Mr. Ault reported conversion of Series B convertible preferred stock into 100,000 common shares at $2.32 per share. The report lists additional holdings indirectly held through related entities (Ault Lending, Ault Life Sciences, and Ault Life Sciences Fund) and warrants and convertible preferred interests held by Ault Lending.

Alzamend Neuro, Inc. (ALZN) Schedule 13D/A amends prior disclosures to report beneficial ownership positions held by Milton C. Ault, III and affiliated entities. The filing states 3,339,861 shares outstanding and reports that Mr. Ault may be deemed to beneficially own 606,321 shares, or approximately 15.9% of the common stock, through a combination of direct holdings, warrants and shares underlying Series B convertible preferred stock held by affiliated entities.

The filing also reports that Hyperscale Data, Inc. and Ault Lending, LLC may each be deemed to beneficially own approximately 15.5% (593,349 and 593,337 shares respectively). Other reporting persons (Horne, Nisser, Cragun, Katzoff) hold much smaller positions, generally representing shares and options exercisable within 60 days. Item 3 discloses sources of funds and aggregate purchase prices for specified holdings and instruments.

Milton C. Ault III, a director and >10% owner of Alzamend Neuro, Inc. (ALZN), reported multiple transactions in September 2025. On 09/19/2025 he disposed of 77,009 common shares at $2.3485, leaving 8,260 shares beneficially owned indirectly through Ault Lending, LLC. On 09/22/2025 he converted Series B convertible preferred stock into 100,000 common shares at a conversion price of $2.32, bringing indirect beneficial ownership through Ault Lending to 108,260 shares. The filing also discloses additional indirect holdings: 11,068 shares held by Ault Life Sciences, Inc. and 61 shares held by Ault Life Sciences Fund, LLC. Derivative holdings include Series B preferred interests and several warrants held indirectly by Ault Lending, LLC.

Milton C. Ault III, a director and >10% owner of Alzamend Neuro, Inc. (ALZN), reported transactions on 09/17/2025 and 09/18/2025. On 09/17/2025 he converted Series B convertible preferred stock into 100,000 shares of common stock at a conversion price shown as $2.32, resulting in a reported beneficial ownership of 108,260 shares (indirect) held through Ault Lending, LLC. Also on 09/17/2025 he sold 2,121 shares at $2.4535 and on 09/18/2025 he sold 20,870 shares at $2.4673, reducing reported indirect holdings to 85,269 shares. Additional small indirect holdings are reported through Ault Life Sciences, Inc. and Ault Life Sciences Fund, LLC. The Form 4 is signed 09/19/2025.

Alzamend Neuro, Inc. reported cash of $5,928,830 at July 31, 2025, up from $4,177,377 at April 30, 2025, and a net increase in cash of $1,672,214 for the period. The company recorded a net loss of $2.7 million for the three months ended July 31, 2025, and used $2.4 million in operating activities during the quarter. Management states the company expects to continue to incur net losses in the foreseeable future. As of the filing the company reported working capital of $4.9 million, an accumulated deficit of $61.2 million, and stockholders' equity of $5.3 million. The filing discloses that the company has historically financed operations primarily through issuances of equity and debt and details multiple preferred and common equity transactions and conversions completed during the period.

Alzamend Neuro (ALZN) – Schedule 13D/A Amendment No. 6 (filed 08/01/25)

The filing consolidates current beneficial ownership of Milton C. Ault III and eight related reporting persons. Collectively, Mr. Ault, Hyperscale Data (f/k/a Ault Alliance), Ault Lending and affiliated life-sciences entities report 706,321 common shares—about 18.5 % of ALZN’s 3,139,861 shares outstanding as of 07/30/25. The position comprises:

• 8,260 common shares and 23,334 warrant-covered shares held by Ault Lending
• 661,743 shares issuable upon conversion of Series B Convertible Preferred Stock held by Ault Lending
• 12 warrant-covered shares held by Hyperscale Data
• 11,068 shares held by Ault Life Sciences and 61 shares held by Ault Life Sciences Fund
• 1,843 shares held directly by Mr. Ault

Hyperscale Data indirectly controls Ault Lending and therefore shares voting/dispositive power over 693,349 shares (18.1 %). Other insiders—William B. Horne, Henry C.W. Nisser, Kenneth S. Cragun and David J. Katzoff—each hold <0.1 % via small share and option positions. No reporting person has been convicted of, or sanctioned for, securities violations within the last five years, and no new transactions occurred in the past 60 days. Aside from the updated ownership table and principal-occupation details, prior disclosures remain unchanged.